Company Glenmark Life Sciences Limited Bombay S.E.

Equities

GLS

INE03Q201024

Pharmaceuticals

Market Closed - Bombay S.E. 03:30:47 10/05/2024 pm IST 5-day change 1st Jan Change
826.4 INR -1.01% Intraday chart for Glenmark Life Sciences Limited -0.37% +25.76%

Business Summary

Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

Number of employees: 1,824

Sales per Business

INR in Million2022Weight2023Weight Delta
Generic
93.0 %
19,154 90.2 % 20,099 93.0 % +4.93%
CDMO
7.0 %
1,720 8.1 % 1,513 7.0 % -12.05%

Sales per region

INR in Million2022Weight2023Weight Delta
India
52.4 %
21,232 100.0 % 11,330 52.4 % -46.64%
International
47.6 %
-- 10,282 47.6 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 58 13/19/13
Director of Finance/CFO - 01/22/01
Compliance Officer - 23/21/23
Chief Tech/Sci/R&D Officer - 14/20/14
Director/Board Member - 12/20/12
General Counsel - 01/19/01
Human Resources Officer 49 11/18/11

Members of the board

Members of the board TitleAgeSince
Director/Board Member 66 30/20/30
Chief Executive Officer 58 13/19/13
Human Resources Officer 49 11/18/11
Director/Board Member 64 08/21/08
Director/Board Member - 12/20/12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 122,527,172 19,263,516 ( 15.72 %) 0 15.72 %

Shareholders

NameEquities%Valuation
Nirma Ltd.
75.00 %
91,896,285 75.00 % 854 M ₹
9,609,571 7.843 % 89 M ₹
NTAsset (Thailand) Co., Ltd.
0.7759 %
950,648 0.7759 % 9 M ₹
Old Bridge Asset Management Pvt Ltd.
0.1197 %
146,642 0.1197 % 1 M ₹
Nippon Life India Asset Management Ltd. (Invt Mgmt)
0.0134 %
16,479 0.0134 % 153 187 ₹
Motilal Oswal Asset Management Co. Ltd.
0.008774 %
10,751 0.008774 % 99 940 ₹
SBI Funds Management Ltd.
0.007558 %
9,260 0.007558 % 86 080 ₹
HDFC Asset Management Co. Ltd. (Invt Mgmt)
0.004430 %
5,428 0.004430 % 50 458 ₹
Groww Asset Management Ltd.
0.000516 %
632 0.000516 % 5 875 ₹
Edelweiss Asset Management Ltd.
0.000507 %
621 0.000507 % 5 773 ₹

Company contact information

Glenmark Life Sciences Ltd.

4th Floor, OIA House 470 Cardinal Gracious Road

400099, Mumbai

+91 22 6829 7979

http://www.glenmarklifesciences.com
address Glenmark Life Sciences Limited(GLS)

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
827.8 INR
Average target price
905.8 INR
Spread / Average Target
+9.42%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. GLS Stock
  4. GLS Stock
  5. Company Glenmark Life Sciences Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW